Georgia has recently granted fast-track approval for an open-label study, which serves as an extension for patients with epilepsy who have successfully completed a double-blind study and are eager to continue into the next phase.
The approval was granted in just three weeks, marking an impressively quick turnaround compared to typical approval times in other regions.
The first patient rollover was successfully achieved in April. This expedited approval is expected to significantly accelerate the development of new treatment options for epilepsy patients.
A big congratulations to the Sponsor and GCT team for their hard work in ensuring the trial moves forward smoothly and efficiently!